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Abstract
Hyperhomocysteinemia (hHCy) is a recognized comorbid risk factor of human brain
stroke. We overview here the recent data on the homocysteine (Hcy) metabolism and
on the genetic and metabolic causes of hHCy‐related neuropathologies. In context of
our results which detected an increased oxidative stress in hyperhomocysteinemic rats,
we discuss here the role of free radicals in this disorder. Brain ischemia‐reperfusion
causes delayed neuronal death. Ischemic tolerance evoked by preconditioning (IPC)
represents a phenomenon of central nervous system (CNS) adaptation to any subse‐
quent ischemia. The paper describes changes in the mitogen‐activated protein kinases
(MAPKs) protein pathways, and apoptotic markers were used to follow the degenera‐
tion process.  Our studies  provide evidence for  the  interplay and tight  integration
between  extracellular  signal‐regulated  kinase  (ERK)  and  p38  MAPKs  signaling
mechanisms in response to the hHCy and also in association with brain ischemia/IPC
challenge. Recognition of the effects of risk factors in the ischemic tolerance would lead
to improved therapeutics, especially the brain tissue.
Keywords: hyperhomocysteinemia, ischemic tolerance, oxidative stress, brain, pre‐
conditioning
1. Introduction
Comorbidities are widely recognized as possible risk factors for cardiovascular and cerebro‐
vascular diseases [1–4]. Clinically described comorbidities such as earlier incidence of any type
of stroke, prior transient ischemic attack (TIA), arterial disease, atrial fibrillation, unproper
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diet and/or obesity, and physical inactivity are known to elevate risk for ischemic stroke [3, 4].
As it has been proved by several studies, even mild hyperhomocysteinemia (hHCy) increases
the incidence of ischemic brain damage, probably due to pleiotropic effect of homocysteine
(Hcy) and the impact of venous and arterial atherosclerotic changes [2, 5–7]. In fact, Hcy
inhibits NO synthesis by endothelial cells and platelets and stimulates the production of
reactive oxygen species (ROS) by the release of arachidonic acid from platelets. In parallel, it
also inhibits glutathione peroxidase and therefore stimulates the proliferation of endothelial
cells (see [6] for review). In addition, Hcy has been shown to inhibit methyltransferases, to
suppress DNA repair, and to facilitate apoptosis when accumulated inside the cells. Auto‐
oxidation of Hcy metabolites results in H2O2 accumulation [8], and long‐term incubation of
neurons with Hcy metabolites induces necrotic cell death [9]. Consequently, homocysteine
level has been shown to be comorbidly elevated in neurodegenerative and acute disorders of
the central nervous system (CNS), for example, Alzheimer's disease or Parkinson's disease
[10]. Thus, the incorporation of animal models more consistent with the clinical population
afflicted by stroke is urgently needed for proper exploration of the disease's etiology such as
stroke and other cerebrovascular diseases. In fact, only limited number of literature data can
be found to describe the mutual influence of comorbid hyperhomocysteinemia to ischemic
damage on animal models of ischemic stroke.
2. Phenomenon of ischemic tolerance evolution
The brain is highly susceptible to hypoxia or ischemia, and numerous endogenous mechanisms
exist to protect neural tissue from its effects and to produce a protective state known as ischemic
tolerance [3, 4, 11]. It represents an evolutionally conserved endogenous neuroprotection/
plasticity, which can be induced by various paradigmas/stressors. Preconditioning is one of
the recognized neuroprotective strategies, which is induced prior to stroke as a preventative
measure in a high‐risk individuals. It also can be used as a precaution against secondary stroke
following medical procedures such as aneurysm repair or cardiac surgery [1, 3, 4, 12]. In the
clinical settings of human stroke, which is hardly predicted, a novel algorithm of postcondi‐
tioning may have a very high therapeutic value. Remarkably, it could be used afterward of
ictus to stimulate protective and regenerative pathways or as a precaution against stroke
recurrence [1, 12, 13]. Clinical studies are needed to test the safety and efficacy of these novel
strategies in humans [3, 4]. Although the cascade of molecular processes determining ischemic
preconditioning is not fully understood, it has been shown to influence receptor activities,
mitogen‐activating protein (MAP) and other kinases and apoptotic mechanisms. Additionally,
ischemic tolerance in the brain can also be stimulated remotely, for example, by the application
of a tourniquet to one of the limbs also in human patients with subarachnoid hemorrhage.
More detailed studies are still needed to clinically validate this phenomenon [1, 3, 12, 14–16].
In spite of the high clinical relevance, only limited number of experiments can be found in the
literature to describe the mutual influence of comorbid hyperhomocysteinemia to ischemic
damage on animal models of human stroke. This paper summarizes current knowledge of the
homocysteine metabolism and the genetic and the metabolic causes of hyperhomocysteine‐
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mia‐related neurotoxicity. Based on results from our laboratory, in this context, we also found
that the combination of experimental hyperhomocysteinemia (hHCy) with ischemic insult
and/or with the pre‐ischemic challenge affects the extent of neuronal degeneration as well as
the MAP kinase pathways involved in the preconditioning phenomenon.
3. Toxicity of homocysteine as recognized from its metabolism
Homocysteine (Hcy) is an intermediate sulfhydryl‐containing amino acid derived from
methionine with recognized toxicity to neural cells and vascular endothelial cells. It originates
from a dietary protein through S‐adenosyl methionine conversion [17]. Human patients with
severe hyperhomocysteinemia (hHcy) are characterized by a perplex of typical clinical
cardiovascular manifestations, which include neurological abnormalities, such as cerebral
atrophy, dementia, and seizures [18]. A large number of epidemiological investigations have
revealed the association of folate deficiency and hyperhomocysteinemia with an increased risk
of vascular diseases and brain ischemic stroke [6, 19].
Homocysteine metabolism includes three independent alternative pathways:
i. re‐methylation,
ii. transmethylation to methionine, or
iii. transsulfuration to cysteine.
In addition to the already recognized causative role of mutations or polymorphisms in the key
genes encoding enzymes of Hcy metabolism to cardiovascular disorders and also stroke, a
novel observation already proved that epigenetic mechanisms, such as DNA methylation,
chromatin remodeling, RNA editing, noncoding RNAs (ncRNAs), and microRNAs (miRNAs),
might be equally relevant in the stroke etiopathogenesis [3, 20]. Earlier genetic studies suggest
that polymorphisms of the genes, which encode the metabolic pathways, such as methylene‐
tetrahydrofolate reductase (MTHFR), cystathionine β‐synthase (CBS), DNA methyltransferase
(DNMT), and nicotinamide N‐methyltransferase (NNMT), might play an important role in
stroke development during elevated level of Hcy. Additionally, nutritional supplements, for
example, folic acid (a cofactor in one‐carbon metabolism), can regulate the epigenetic altera‐
tions of neuronal cells and may play an important role in the maintenance of neuronal
integrity [18, 20].
General Hcy metabolism in liver represents mainly methyl group transfer and re‐methylation
and requires vitamin B12 and folic acid for N‐5‐methyltetrahydrofolate‐homocysteine methyl‐
transferase. Additionally, the transsulfuration reaction of Hcy depends on the presence of
vitamin B6. Remarkably in the CNS, the Hcy metabolism differs from other organs. The
transsulfuration pathway is practically absent and the re‐methylation pathway using betaine
is not present [6, 21]. Thus, the effectivity to metabolize or convert homocysteine mostly relies
on externally delivered folate and cobalamine in the form of vitamins. The glial cells contain
very low deposits of vitamin B12, which is exhausted rather quickly during its negative balance.
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The harmful effect of the homocysteine to CNS neurons is quite well known. It has an influence
to both the neuronal survival rate and the functionality of neurons to the signal transmission.
As a consequence, it also affects the formation of functional neural networks with the effect
surpassing simple neuronal survival.
In our laboratory, we have analyzed the neurotoxic properties of Hcy on glial cells, using a
glioblastoma cell line as a study model. The viability of cells was assayed both biochemically
and cytologically. As proved, Hcy concentration around 50 μmol/l induced cell death. It is
worth noting that Hcy induces cell death of human glial cells at concentrations which corre‐
sponds to the mild clinically occurred hyperhomocysteinemia. We propose that Hcy‐induced
impairment of neuronal functions along with the damage of glial cells may contribute to the
etiopathogenesis of neurological disorders associated with hyperhomocysteinemia [22]. As
shown in clinical studies, an elevated Hcy level associates with CNS disorders, such as stroke,
Alzheimer's disease, dementia, as well as with classical homocystinuria [2, 6].
In humans, plasma Hcy concentration varies from 5 to 10 μmol/l and its elevated level is
classified as hyperhomocysteinemia (hHcy) with mild, moderate, intermediate, and severe (for
concentrations higher than 100 μmol/l), manifested also with homocystinuria [19]. As gener‐
ally believed, homocysteine is produced merely in all tissues. On the other hand, its metabolic
inactivation proceeds only in the liver/kidney, mainly through the transsulfuration pathway.
As the outcome, in tissues such as the blood vessels and the brain, where re‐methylation
enzymes are merely absent, the reduction of MTHFR activity leads to homocysteine accumu‐
lation. As analyzed in various genetic cohorts, the MTHFR C677T polymorphism has been
established as a risk factor for ischemic stroke in different laboratories [23].
Selective neurotoxic effect of Hcy includes various pathomechanisms such as glutamate
receptor‐mediated neurotoxicity [2, 24]. Notably, glutamatergic excitotoxicity is also associated
with the brain damage caused by ischemic insult. Hcy was shown as an inductor of caspase‐
dependent neuronal apoptosis, by a mechanism involving several detrimental steps, such as
the DNA damage, poly‐ADP‐ribose polymerase (PARP) dysregulation, and mitochondrial
dysfunction by caspase‐3 activation. Hcy appears to also be critically involved in the glial‐
vascular interface communications as part of the blood‐brain barrier. The important role of
astrocytes in the regulation of overall brain metabolism and in particular in the brain energy
metabolism has already been proved [4, 22]. As generally believed, the elevation of the Hcy
activates an excitatory glutamatergic neurotransmission in different brain areas, which
stimulates neuronal damage derived from an excessive Ca2+ influx and reactive oxygen species
generation.
Principally, dysbalance in redox state and oxidative stress has been proposed as one of the
primary etiologies for hHCy‐related pathogenesis [6, 19]. Previous observations proved that
dysequilibrium in redox balance may be a key factor in the pathogenesis of vascular hyper‐
trophy, thrombosis, and atherosclerosis in hyperhomocysteinemic animals [25]. In fact,
reactive oxygen species (ROS) are side products of the Hcy‐free thiol group oxidation, mainly
when Hcy binds via a disulfide bridge with plasma proteins—mainly albumin— or with other
low‐molecular plasma thiols, or secondarily with other Hcy molecule.
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Already proposed reactions responsible for Hcy‐induced oxidative stress include:
i. inhibition of the activity of cellular antioxidant enzymes,
ii. Hcy auto‐oxidation,
iii. nitric oxide synthase (NOS)‐dependent generation of superoxide anion via uncou‐
pling of endothelial NOS (eNOS),
iv. disruption of extracellular superoxide dismutase from endothelial surfaces, and
v. activation of NADPH oxidases.
vi. Interestingly, mutual tissue production of strong oxidant peroxynitrite stimulates
tyrosine nitration, which leads to protein functional alterations and cellular dysfunc‐
tion [26]. Auto‐oxidation of Hcy metabolites results in H2O2 accumulation and as
shown by [9] and later by [8] prolonged incubation of neurons with Hcy metabolites
leads to necrotic cell death.
Homocysteine is also converted to the thioester forming the Hcy‐thiolactone in an error‐editing
reaction in translation mechanism. Accidentally in proteosynthetic process, Hcy is erroneously
selected in place of methionine by methionyl‐tRNA‐synthetase. As shown by animal and
human experiments, the Hcy‐thiolactone remarkably contributes to Hcy pathobiology. Its
toxicity is based on reaction which leads to protein N‐homocysteinylation through the
formation of amine bonds with protein lysine residues [27], which impairs or alters the
structural and functional properties of particular protein. Several clinical studies have reported
that increased plasma homocysteine levels may provoke neurological seizures. Systemic
administration of homocysteine at high doses is able to induce convulsions in mice and it can
be suggested that similar detrimental effects might occur in patients affected by temporal lobe
epilepsy [28].
A number of papers from our and also other laboratories [13, 29–31] documented that global
ischemia/reperfusion injury (IRI) in rats follows with the time‐dependent dysbalance of redox
balance in cortex and hippocampus. The insult also activates different gene expression at both
the mRNA and protein levels. In addition, experiments of [32] proved that the redox status
and gene expression are influenced by preconditioned pre‐ischemic treatment. In spite of high
clinical relevance, the data from literature which deals with the mutual effect of IRI and
endogenously produced homocysteine as verified risk factor to ischemic injury are very
limited [2]. Observations of [6] which described the effect of chronic dietary supplementation
of Hcy for 2 weeks (to initiate hyperhomocysteinemia‐hHCy) documented remarkable
elevation of lipoperoxidative and protein oxidative products in rat cortex and hippocampus.
Experimental hyperhomocysteinemia was induced by the subcutaneous administration of
homocysteine in saline solution (0.45 μmol/g body weight) twice a day at 8‐h interval for 14
days [6, 30]. It has been proved that Hcy crosses the blood/brain barrier and exhibits a
maximum level in the cerebrum and parietal cortex between 15 and 60 min after subcutaneous
injection. Remarkably, plasma Hcy concentration in rats treated this way achieved levels
similar to those found in homocystinuric patients (moderate hyperhomocysteinemia). Groups
of rats were subdivided as described earlier [6, 30]:
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1. sham‐operated control (naive) animals,
2. sham‐operated control (preconditioning) animals,
3. the animals that underwent 15‐min ischemia (naive),
4. the animals with induced 5‐min IPC following 15‐min ischemia,
5. sham‐operated hyperhomocysteinemic control animals,
6. the hyperhomocysteinemic animals that underwent 15‐min ischemia,
7. the hyperhomocysteinemic animals with induced preconditioning animals following 15‐
min ischemia.
Experiments evidently document that hyperhomocysteinemia induces remarkable elevation
of lipoperoxidative and protein‐oxidative products, the results which are in a good correlation
with previously published experiments [24]. Moreover, as documented by the number of
Fluoro‐Jade B‐positive‐ and TUNEL‐positive cells (as indicator of neuronal degeneration) [30,
33–37], the number and proportion of degenerated neurons over intact cells evidently exceeds
in the hippocampus of hHCy animals and reached the level which almost competes with the
levels documented after ischemic insult in nontreated, naive group. As was shown in earlier
studies, an auto‐oxidation of Hcy metabolites results in higher H202 production, and prolonged
incubation of neurons with Hcy metabolites elevates the number of necrotic cell death [8, 9].
Interestingly, as was documented by [38], single intracerebroventricular injection of homocys‐
tein was followed by the elevation of typical apoptotic features of cells of substantia nigra, which
results to the typical Parkinson's disease‐like behavior in rats. As was detected earlier, an
increased Hcy level is potent to induce and accumulate hydroxyl radicals as the most potent,
powerful‐free oxygen species with the high efficiency to remove electrons from other cellular
biomolecules such as lipids, proteins, carbohydrates, and DNA [39]. Remarkably, results of
experiments from our laboratory and also previous results have documented that in hyper‐
homocysteinic model in rats [6, 30, 36, 37, 40], the elevation of homocysteine was followed by
significant neurotoxic effect. As was proposed earlier, the effect is probably caused by the
hHCy‐induced oxidative dysbalance and cellular stress. Interestingly, as was detected in a
human study on Alzheimer's patients and patients with the mild cognitive impairment, an
increased level of plasma homocysteine positively correlated with alterations of hippocampal
volume. This effect is not mediated by cerebral beta‐amyloid deposition and vascular burden
but likely due to the oxidative dysregulation induced by homocysteine as part of direct
homocysteine adverse effect [2, 41].
Results from another study from this laboratory [42] have shown that hyperhomocysteinic
differently express mRNA and protein of calcium pump in secretory pathways (SPCA1). SPCA
has a remarkable role in the development of neural cells and their migration [43] and its loss
can finalize to the stress of Golgi apparatus expressed by alterations of membrane structure
and redox dysregulation in neuronal cells. The effect of Hcy on the expression profile of the
Ca2+‐transport proteins in neuronal cells is not yet fully described. The transcription factors
Sp1 and YY1 were identified in the gene expression regulation by the cis‐enhancing elements
in 5’‐untranslated regions. Hyperhomocysteinemia is followed in intracellular Ca2+ elevation,
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release of calcium and endoplasmic reticulum (ER) stress [6, 44], leading to apoptotic events,
endothelial dysfunction, and remodeling of the extracellular matrix also in the brain paren‐
chyma. Moreover, homocysteine itself by metabolic interfering with the level of S‐adenosyl‐
methionine (donor of methyl group) has also been reported to induce the modulation of gene
expression through the alteration of the gene methylation status [10].
Remarkably, the processes, such as modifications of protein structure, have been proved in the
etiology eventually leading to homocysteine‐induced neurotoxicity. Homocysteinylation can
be subdivided into the two main types:
i. S‐homocysteinylation and
ii. N‐homocysteinylation,
both of which are typical examples of posttranslational protein modifications. The extent of
the homocysteinylated modifications correlates with increased plasma Hcy level [39], and the
chemical conversion of Hcy to Hcy‐thiolactone followed by protein N‐homocysteinylation is
an etiological factor, which contributes to the expressed Hcy neuronal and tissue toxicity. As
shown by [45], homocysteinylation follows functional protein modification and enhances
protein degradation processes which can finalize to cell damage.
In this context, Petras et al. [6] in a recent study observed remarkable decrease of Mn2+‐activated
superoxide dismutase (Mn‐SOD) activity in cortical mitochondria in the 14‐day hHCy model
in rats. This catalytic activity is included in the first line of cellular defense against oxidative
injury, and has been shown to be suppressed in the hHCy group compared to the control group.
These results might be explained by putative increased posttranslational modifications of Mn‐
SOD due to the higher level of Hcy leading to the enzyme homocysteinylation and thiolation.
As was shown recently by Li et al. [46], the imbalance among antioxidant enzymes caused by
an increased Hcy level might alter ROS elimination, and thus lead to the increasing amount of
free radicals and likely to homocysteine‐induced stress of endoplasmic reticulum, which can
result in the dysfunctional consequences in rat hippocampus.
4. Impact of hyperhomocysteinemia on ischemic/reperfusion injury and
ischemic tolerance induced by ischemic preconditioning
Now, the clinical comorbid effect of hHCy to the stroke incidence and severity is clearly
recognized. However, a bit surprisingly, the experimental results, which are focused on the
mutual influence of the comorbid hyperhomocysteinemia to ischemic damage on the animal
models of human stroke, are only limited [12, 32, 47]. Ischemic insult/reperfusion insult in the
animal models is followed by the degeneration of majority (more than 64%) of hippocampal
neurons [3, 33]. Experiments from this laboratory [33, 34, 42], which combine 14 days of
hyperhomocysteinemia with 15‐min forebrain ischemia/reperfusion, show that insult initiates
manifestations of morphologically changed neurons and disturbances of glial cells of the
hippocampal area. On the other hand, the combination of both approaches elevated the
percentage of morphologically intact and probably nondegenerated cells in comparison to the
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naive ischemic/reperfusion insult. In this context, Sato et al. [47] in experiments on hippocam‐
pal CA1 neurons after ischemic insult in rats have proved concentration‐dependent cell
protection by S‐adenosyl‐l‐methionine (SAMe). The effect was concealed by the concomitant
administration of S‐adenosyl‐l‐homocysteine, a potent inhibitor in transmethylation. From
these results, the authors considered that the enhancement of intraparenchymal SAMe level
followed by the activation of transmethylation using SAMe as a methyl donor in postischemic
brain is inevitable for the tissue protection and prevention of delayed neuronal death.
The pre‐ischemic treatment has been recognized to save the majority of hippocampal neurons
which exceeds more than 75% of all neurons [1, 33]. If we combined 14 days of hyperhomo‐
cysteinemia with preconditioning [6, 33, 34, 36, 37, 40, 42], this particular treatment has
finalized by the larger suppression of cell degeneration not crossing 5% of the total number of
neurons. It is remarkable that in this particular hyperhomocysteinic model in rats, the
protective effect of IPC maneuver is influenced by not‐yet fully clarified mechanism. One
appealing candidate that has been described is a novel regulatory epigenetic mechanism,
which encompasses both the gene environment interactions and also tissue functionality. The
recent evidence proves that several epigenetic mechanisms are also involved in the stroke
pathogenesis and the tolerance etiology. Participation of several important enzymes regulating
DNA methylation including DNA‐N‐methyltransferase has been proved, and the high level
of Hcy may eventually finalize to the increase in the level of S‐adenosyl methionine. As a result,
its higher enzymatic activity might stimulate hypermethylation of the genomic DNAs and
silencing of functional genes [44].
In the recent study [35], the authors have analyzed whether hyperhomocysteinemia (risk factor
of brain ischemia) alone or in combination with the ischemic preconditioning (IPC) affects the
ischemia‐induced neurodegenerative changes and imbalance in the intracellular‐signaling
pathway including the MAPK/p‐ERK1/2 and MAPK/p‐p38 gene and protein expression in the
rat brains. We have used the model of hyperhomocysteinemia induced by the subcutaneous
administration of homocysteine as well as the preconditioning maneuvers followed by global
ischemia as was described above. Here, we suggest that hHCy alone (as an example of
metabolic stress) and/or in combination with IR injury affects mechanisms of the ischemic
tolerance induced by IPC maneuver. The study reveals that hHCy alone significantly increased
neurodegeneration by Fluoro‐Jade C and terminal deoxynucleotidyl transferase (TdT)‐
mediated dUTP nick end labeling (TUNEL) positive cells in hippocampus as well as in the
cortical brain area. Prominent features of those changes were detected by using markers of cell
damage/degeneration and changes in MAPKs expression in the CA1 hippocampal region and
M1 cortical sector. We have also found in these experiments an elevated level of MAPK/p‐ERK
and the decreased level of MAPK/p‐p38 after pre‐ischemic challenge by Western blot and
fluorescent immunohistochemistry.
Experiments from this laboratory previously showed that IR insult leads to the neurodegen‐
eration of neurons in the CA1 region of hippocampus as detected by Fluoro‐Jade C and TUNEL
analysis. As expected, IPC leads to the suppression of the number of positive cells and
conferred neuroprotection [33, 34]. Interestingly, the effect of homocysteine on cellular
degeneration and following morphological changes was observed in the rat hippocampal and
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cortical regions. The increased number of Fluoro‐Jade C+ and TUNEL+ neuronal and glial
elements supports this effect of hHCy. The thickened and collapsed processes that poorly
extend to the area of pyramidal neurons in CA1 region and M1 cortex are presumably due to
the morphological alterations of astrocytes and cytoskeletal remodeling. This might suggest
for the ensuing development of hHCy‐associated neuronal cell damage [23, 48, 49]. Astrocytes
are highly plastic cells and their dynamic morphological changes could affect the intercellular
communication with surrounding synapses that are important in the development of brain
lesions [40]. Maler et al. [50] reported that Hcy doses of 2 mmol/l and above induced a dose‐
dependent cytotoxic effect on cortical astrocytes. Astrocytes regulate the expression of the N‐
methyl‐d‐aspartate (NMDA) receptor subtypes, which increase neuronal sensitivity to
glutamate toxicity and thus accelerate the initial step in a program of reactive astrogliosis and
dynamics of the astrocyte response to damage [51]. On the other hand, in response to the injury,
astrocytes synthesize a number of factors that may play either neuroprotective or neurotoxic
roles.
Recently, we have shown that IPC prior to lethal ischemia affects MAPK/ERK and MAPK/p38
pathways in the cerebral cortex [33] as well as in hippocampus [34]. There is only sparse
literature data focusing on the effect of Hcy on the MAPKs protein expression in neuronal cells
[48, 52]. Our results suggest that the combination of both stressors (ischemia + Hcy) affects
considerably the MAPKs pathways expression. hHCy‐IR induces the MAPK/p38 expression
as detected by Western blot and immunoanalysis. Poddar and Paul [52] showed a biphasic
response of MAPK/p38 activation in the Hcy‐NMDA‐induced neuronal damage in vitro,
characterized by the initial rapid elevation followed by a delayed and more prolonged
secondary increase, where the later peak was primarily involved in mediating the Hcy‐induced
cell death. They also showed that this secondary activation of MAPK/p38 correlates with the
upstream MAPK/ERK activation, which plays a role in facilitating of the Hcy with the
conclusions of this study. Interestingly, we found that the MAPK/p38 pathway was activated
also in hHCy control group. We previously reported that IR injury induces only slight increase
of MAPK/p38 expression [33, 34]. However, the combination of both stressors (ischemia +
hHCy) leads to the massive activation of MAPK/p‐p38 with maximum at 24 h after reperfusion.
This dynamic MAPK/p38 activation could contribute to more extensive progression of tissue
injury [52, 53]. Remarkably, the effect of the IPC maneuver on the decreasing of MAPK/p‐p38
expression in ongoing reperfusion times indicates for proposed neuroprotective mechanism.
The MAPK/p‐p38 pathway was suppressed also by the combination of two stressors.
MAPK/ERKs are versatile protein kinases that are ubiquitously expressed in the CNS. We have
already shown that in the hippocampus and cerebral cortex activated MAPK/ERK parallels
neuroprotection induced by IPC [33, 34]. The robust expression changes in hippocampus and
modest posttranslational changes in MAPK/ERK pathway in less sensitive vulnerable neurons
of the cortical layers III and V corresponds with results of similar experimental models [53,
54]. Extensive studies have shown an interplay and tight integration of MAPK/ERK signaling
in promoting neuronal cell death both in development and in neurodegenerative disorders
[49, 52]. It has been proposed that transient activation of MAPK/ERK has different consequen‐
ces as compared with sustained activation [49, 52]. Transient activation of MAPK/ERK plays
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a pivotal role in neuronal maturation, survival, and long‐term potentiation. On the other hand,
the sustained activation of MAPK/ERK may play a critical role in triggering proapoptotic
signals and neuronal cell death. As documented in our study [35], the immunoreactivity of
MAPK/p‐ERK after IPC with induced hHCy was found in the early stages of reperfusion, with
maximum level at 24 h, and its activation is probably associated with neuronal protection
induced by IPC [54]. The slight activation of MAPK/ERK was detected also in the hHCy‐ control
group. It is well known that hHCy mediates glutamate‐mediated NMDA receptor stimulation,
which eventually leads to the activation of both stimulatory and inhibitory pathways involved
in the modulation of MAPK/ERK signaling [49]. In fact, the dual role of MAKP/ERK kinases
in cell survival and death suggests that a unique profile of gene expression may be elicited
depending on the duration and/or magnitude of MAPK/ERK kinase activation [52]. Thus, the
duration of MAPK/ERK kinase activation following MAPK/p38 stimulation depends on the
nature of the extracellular stimuli and may have different consequences on intracellular
signaling pathways eventually leading to different cellular responses.
To summarize, results from our and other experiments show that hHCy is associated with a
selective degeneration of cortical and limbic brain structure including hippocampal area. The
degeneration involves the loss of neurons, glial growth, hypertrophy of astrocytes, and
probably sprouting of new connections. The morphological findings indicate that the astro‐
cytes are the first neural cells participating in the deleterious actions of Hcy on the CNS.
Apparently, astrocytes are able to respond to mild hHCy by reorganizing their cytoskeleton,
surviving and protecting neurons from the damage [55].
Moreover, our studies also suggest that there are at least two different ways in which the
neuronal tissue responds to hHCy. The induction of hHCy alone leads to neuronal cell death
and morphological changes in the hippocampus and cortex that corresponds with findings of
previous reported studies [48, 55, 56]. Combination of hHCy with more intense stimuli
(ischemia) causes more prominent changes in cortex than in hippocampus. Importantly, IPC
maneuver, even if combined with hHCy, still preserves the neuronal tissue from lethal ischemic
effect. The other important finding that arose from our studies is that MAPK/p38 promotes
neuronal cell death, whereas MAPK/ERK activation opposes apoptosis. Finally, all the above‐
mentioned studies provide evidence for the interplay and tight integration between ERK and
p38 MAPK‐signaling mechanism in response to mild hHCy and also in association with IR
insult/IPC challenge in rat brain. Conclusively, preconditioning even if combined with hHCy
could still preserve the neuronal tissue from lethal ischemic effect.
The one carbon unit metabolic pathway, which is involved in the regulation of homocysteine
metabolism, is also part of the process which methylates amino acids in functional proteins
and histones as well as the bases within the RNA and DNA. As a result, demethylation of S‐
adenosyl methionine, which is converted to S‐adenosyl‐homocysteine, exclusively provides
methyl groups for the cells. Derangement of this phase might cause wide implications on
plenty of cellular processes including the modulation of the expression of functional genes as
well as the epigenetic regulation [10, 44, 21].
Elimination of Hcy‐thiolactone, a metabolite of HCy, is performed by the high‐density
lipoprotein (HDL)‐associated enzyme, Hcy‐thiolactonase/paraoxonase 1 (PON1). This enzyme
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hydrolyzes Hcy‐thiolactone in human serum [57] and similarly in the brain, it has been
proposed that PON1 protects mice against Hcy‐thiolactone neurotoxicity by enzymatic
hydrolysis [58].
In summary, the experiments proved that pre‐ischemic challenge in 14 days of hyperhomo‐
cysteinemic model in rats initiates responses of neuronal cells, which probably coordinate
several etiological/protective mechanisms such as antioxidant defense [58], Ca2+ transport, and
epigenetic mechanisms, such as DNA methylation and chromatin remodeling in the manifes‐
tation of the phenomenon of ischemic damage and ischemic tolerance [1, 12, 20, 32, 33].
5. Conclusion, challenges, and future directions
Hyperhomocysteinemia manifested as an elevated plasma level of homocysteine is now a
widely recognized risk factor of human ischemic stroke. Elevated plasma homocysteine level
leads to an increase in cerebrovascular permeability and causes several biochemical alterations
such as thiolation and homocysteinylation to plasma proteins and enzymes and remarkably
also in the brain parenchyma. These hHCy induced posttranslational protein modifications
can have a causative role to the altered function and activity of the functional enzymes involved
in the free radical protection also in brain parenchyma. Homocysteine metabolism itself leads
also to the redox imbalance and to increased oxidative stress and the production of free radicals
with the consequence in the damaging neuronal lipoperoxidation and cellular protein
oxidation. The paper also highlights protective effect of pre‐ischemic challenge to the subse‐
quent lethal ischemia in rats. The pre‐ischemic maneuver itself and also combined with
hyperhomocysteinemia diminished the extent of neuronal degeneration as well as the
intracellular signaling. Recent studies also underscore an opposing effect of MAPK/ERK and
MAPK/p38 on cell survival and cell death in hyperhomocysteinemic conditions in brain
parenchyma also if combined with IPC challenge in rat model of global ischemic stroke.
Interestingly, a novel protective paradigm, such as postconditioning and/or remote condition‐
ing, has already been observed as an effective in reducing ischemic reperfusion injury. As was
proved in the experimental studies and also in clinical trials, those paradigms affect all the cells
of the neurovascular network (consisting of neurons, glial cells, vascular endothelial cells,
pericytes, smooth muscle cells, and venule/veins) [59, 60]. In the context of clinical applications,
it is strongly suggested that the identification of the effects of comorbid factors in the mecha‐
nisms of ischemic damage and if combined with the ischemic tolerance evolution can poten‐
tially lead to improved therapeutics, especially the brain tissue. Additional studies of these
molecular pathways are strongly needed to validate the role of hHCy in the etiology of
neurological disorders.
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